ArticleOncotarget2017
LEF1, TFE3, and AR are putative diagnostic markers of solid pseudopapillary neoplasms.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Aggressiveness of solid pseudopapillary neoplasm of the pancreas: A literature review and meta-analysis.Medicine · 2018Pooled it
- Sex hormone receptor signaling networks drive pancreatic solid-pseudopapillary neoplasm pathogenesis and therapy.Discover oncology · 2025Review
- Solid pseudopapillary neoplasm of the pancreas: A case report.Experimental and therapeutic medicine · 2025Article
- Review
- Lymphoid enhancer-binding factor 1 (LEF1): a reliable immunohistochemical predictive marker for WNT-activated medulloblastoma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Emerging pathological diagnostic strategies for solid pseudopapillary neoplasm of the pancreas: insights from omics and innovative techniques.The journal of pathology. Clinical research · 2025Review
- Diagnostic utility of LEF1 and β-catenin in WNT pathway tumors with CTNNB1 mutation.World journal of surgical oncology · 2025Article
- Solid pseudopapillary neoplasm (SPN) of the pancreas: current understanding on its malignant potential and management.Discover oncology · 2024Review
- Middle-Preserving Pancreatectomy for Multicentric Solid Pseudopapillary Neoplasm in a 10-Year-Old Female.European journal of pediatric surgery reports · 2024Article
- Solid pseudopapillary neoplasm of the pancreas: a retrospective study of 195 cases.Frontiers in oncology · 2024Article
- Endoscopic ultrasound-guided radiofrequency ablation for solid pseudopapillary neoplasm of the pancreas.Endoscopy · 2023Article
- Single-cell RNA sequencing of solid pseudopapillary neoplasms of the pancreas in children.Cancer science · 2023Article
- "Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms.Virchows Archiv : an international journal of pathology · 2022Article
- Solid Pseudopapillary Neoplasms of the Pancreas: a Single-Center Experience and Review of the Literature.Journal of gastrointestinal cancer · 2022Review
- Cystic Neoplasms of the Pancreas: Differential Diagnosis and Radiology Correlation.Frontiers in oncology · 2022Review
- Repeated Resection for Recurrent Metastatic Solid Pseudopapillary Neoplasm of the Pancreas.The American journal of case reports · 2021Article
- A Case of Adult Pancreatoblastoma With NovelFrontiers in oncology · 2021Article
- Clinicopathological and immunohistochemical study of 29 cases of solid-pseudopapillary neoplasms of the pancreas in patients under 20 years of age along with detailed review of literature.Diagnostic pathology · 2020Review
- Molecular Diagnosis of Cystic Neoplasms of the Pancreas: a Review.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020Review
- Solid-pseudopapillary Neoplasms of the Pancreas is still an Enigma: a Clinicopathological Review.Pathology oncology research : POR · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of solid pseudopapillary neoplasms (SPNs) is challenging because some SPNs share many similar morphological and immunohistochemical features with other pancreatic neoplasms. In this study, we investigated potential diagnostic markers of SPN. Based on the SPN-specific upregulated genes from a previous DNA microarray and proteome study, we selected six immunohistochemical markers [beta-catenin, androgen receptor (AR), lymphoid enhancer-binding factor 1 (LEF1), transcription factor for immunoglobulin heavy-chain enhancer 3 (TFE3), fused in sarcoma (FUS), and WNT inhibitory factor 1 (WIF-1)]. We also evaluated the Ki-67 proliferative index to investigate its associations with prognosis. To validate these markers, we studied 91 SPNs as well as 51 pancreatic ductal carcinomas (PDC) and 48 neuroendocrine tumors (NET) as controls. We found frequent and diffuse nuclear expressions of β-catenin (98.9%), AR (81.3%), LEF1 (93.4%), TFE3 (74.7%), FUS (84.6%), and cytoplasmic expression of WIF-1 (96.7%) in SPNs. In contrast, PDCs and NETs showed no expression. (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.